Effect of adjunctive diclofenac with verteporfin therapy to treat choroidal neovascularization due to age-related macular degeneration: Phase II study

Retina

Volumn 27, Issue 6, 2007, Pages 693-700

  Beer, Paul M ^a   Blodi, Barbara A ^b   Boyer, David S ^c   Bradford, Reagan H ^d   Chen, Sanford ^e   Googe Jr , Joseph M ^f   Halperin, Lawrence S ^g   Harvey, Patricia T ^h   Joffe, Leonard ⁱ   Marx, Jeffrey L ^j   Mieler, William F ^k   Vander, James F ^l   Wong, Keye L ^m   Yoser, Seth L ⁿ  

^a Retina Office Pllc   (United States)

^b University Station Clinic   (United States)

^c RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e Orange County Retina Medical   (United States)

^f Southeastern Retina Associates   (United States)

^g Retina Vitreous Consultants   (United States)

^h Med West Medical Centre   (Canada)

ⁱ Retina Associates Southwest PC   (United States)

^j LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

^l WILLS EYE HOSPITAL   (United States)

^m Sarasota Retina Institute   (United States)

ⁿ Vitreo Retinal Foundation   (United States)

more..

Author keywords

Age related macular degeneration; Choroidal neovascularization; Diclofenac sodium; Verteporfin therapy

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; DICLOFENAC;

ABNORMAL VISION; ACUTE BRAIN DISEASE; ADULT; AGED; ANALYTIC METHOD; ARTICLE; BURNING SENSATION; CATARACT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INSTILLATION; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; FOREIGN BODY SENSATION; HUMAN; MALE; MULTICENTER STUDY; MYASTHENIA GRAVIS; OUTCOME ASSESSMENT; PAIN; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; SCORING SYSTEM; STATISTICAL ANALYSIS; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOROIDAL NEOVASCULARIZATION; DICLOFENAC; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 34447297551     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318030e519     Document Type: Article

References (21)

1. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988;32:375-413.
2. Hyman L. Epidemiology of AMD. In: Hampton GR, Nelsen PT, eds. Age-related Macular Degeneration: Principles and Practice. New York: Raven Press; 1992:1-35.
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP Report 1. Arch Ophthalmol 1999;117:1329-1345.
4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 2001;119:198-207.
5. Verteporfin In Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin In Photodynamic Therapy Report 2. Am J Ophthalmol 2001;131:541-560.
6. Visudyne In Minimally Classic CNV (VIM) Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-457.
7. Rogers AH, Martidis A, Greenberg PB, Puliafito CA. Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. Am J Ophthalmol 2002;134:566-576.
8. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 2003;44:2147-2154.
9. Schmidt-Erfurth U, Niemeyer M, Geitzenauer W, Michels S. Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology 2005;112:2061-2069.
10. Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol 1992;36:259-284.
11. Kraff MC, Sanders DR, McGuigan L, Raanan MG. Inhibition of blood-aqueous humor barrier breakdown with diclofenac. A fluorophotometric study. Arch Ophthalmol 1990;108:380-383.
12. Quentin CD, Behrens-Baumann W, Gaus W. [Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens.] Fortschr Ophthalmol 1989;86:546-549.
13. Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991;112:514-519.
14. Rho DS. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg 2003;29:2378-2384.
15. Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of antiinflammatory efficacy. Inflammation 2000;24:357-370.
16. Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. In-flammation 2000;24:371-384.
17. Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci 2003;44:409-415.
18. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-1525.
19. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-304.
20. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:14-22.
21. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004;88:344-347.